1. Advances in understanding genomic markers and pharmacogenetics of Parkinson’s disease
   Félix Javier Jiménez-Jiménez et al, 2016, Expert Opinion on Drug Metabolism & Toxicology CrossRef
2. Assessment of the Telomere Length and Its Effect on the Symptomatology of Parkinson’s Disease
   Tina Levstek et al, 2021, Antioxidants CrossRef
3. Inflammation-related gene polymorphisms associated with Parkinson’s disease: an updated meta-analysis
   Zulvikar Syambani Ulhaq et al, 2020, Egyptian Journal of Medical Human Genetics CrossRef
4. Impact of NQO1 dysregulation in CNS disorders
   Li Yuhan et al, 2024, Journal of Translational Medicine CrossRef
5. Biological functions of selenium and its potential influence on Parkinson's disease
   JOEL H. ELLWANGER et al, 2016, Anais da Academia Brasileira de Ciências CrossRef
6. Transcriptome Analysis of Induced Pluripotent Stem Cells and Neuronal Progenitor Cells, Derived from Discordant Monozygotic Twins with Parkinson’s Disease
   Ivan N. Vlasov et al, 2021, Cells CrossRef
7. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson’s disease
   M.N. Karpenko et al, 2018, Cellular Immunology CrossRef
8. A systematic review and meta-analysis of inflammatory biomarkers in Parkinson’s disease
   Yi Qu et al, 2023, npj Parkinson's Disease CrossRef
9. Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson’s Disease
   Sara Redenšek et al, 2019, Frontiers in Genetics CrossRef
10. Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson’s disease
    Sara Redenšek et al, 2019, Journal of Neuroinflammation CrossRef